Clinical Trial

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-28
notable Trial sites expanded: 6 -> 16 locations 2026-07-28
Trial Details
NCT Number NCT07473700
Lead Sponsor Tectonic Operating Company, Inc.
Conditions Hypertension, Pulmonary, Lung Diseases, Interstitial
Enrollment 25 participants
Start Date 2026-08
Primary Completion 2027-11-21 (estimated)
Study Completion 2027-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-27